CA
TNXP icon

Clearstead Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Clearstead Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$728 Buy
+57
New +$736 ﹤0.01% 2811

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clearstead Advisors's TNXP Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Tonix Pharmaceuticals (TNXP) in Q2 2026: 57 shares worth $728. The stake represents ﹤0.01% of the portfolio and ranks #2811 among its holdings.

103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Clearstead Advisors held 57 shares of Tonix Pharmaceuticals worth $728 as of Q2 2026.
  • Tonix Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2811 holding.
  • 103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.